Remove Hospitals Remove Outcomes Remove Stroke
article thumbnail

The AcT Trial: Tenecteplase vs Alteplase for Acute Ischemic Stroke

RebelEM

Background : Alteplase, a class of medication that converts plasminogen to plasmin leading to fibrin degradation and subsequent clot lysis, has been the standard of care for acute ischemic stroke (AIS) patients that meet eligibility criteria. mg/kg non-inferior to alteplase in the treatment of acute ischemic stroke? vs Alteplase 34.8%

Stroke 134
article thumbnail

Coronary Artery Calcium Trial Fails to Impress

Sensible Medicine

As a skeptic of this imaging test, I saw the headline and thought: finally, we will learn whether patients who have their chest radiated have better outcomes. Better outcomes, such as fewer heart attacks or strokes, or longer life, is why we interact with healthcare. Same with imaging tests. I will come back to this.)

Stroke 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The ARAMIS Trial: DAPT vs Alteplase in Minor Nondisabling Acute Ischemic Stroke

RebelEM

Background: Current stroke guidelines recommend IV alteplase for patients with acute ischemic stroke presenting within 4.5hrs of symptom onset based on the NINDS and ECASS III publications. Both NINDS and ECASS III excluded patients with mild stroke symptoms but failed to clearly define a threshold for mild stroke.

Stroke 98
article thumbnail

CDC gives a nudge to hospitals on sepsis care

PulmCCM

The Centers for Disease Control and Prevention formally called on hospitals to develop robust sepsis care programs to systematically identify and treat sepsis, track outcomes, and improve care delivery. Unlike strokes and STEMIs, sepsis has no gold standard for diagnosis. ” What is that, a sepsis Stasi?

CDC 98
article thumbnail

52 in 52 – #38: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

EMDocs

This week we cover the EXTEND trial looking at thrombolysis up to 9 hours after stroke onset. and 9 hours after onset of symptoms, with non-infarcted brain tissue, does the administration of alteplase improve functional outcome at 90 days? Intervention: Alteplase 0.9 in alteplase group versus 0.9% to 53.54, p=0.053).

Stroke 98
article thumbnail

52 in 52 – #40: DIRECT MT – Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke

EMDocs

Study design: Multicenter open label randomized control trial Enrolled patients from 41 tertiary care hospitals in China Assessing for statistically significant difference in modified Rankin score at 90 days PICO: Population: 206 patients were enrolled with 107 in the intervention group and 99 in the control. hours of stroke onset.

Stroke 95
article thumbnail

52 in 52 – #39: DAWN – Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

EMDocs

A second primary outcome was added at the 30-month time frame by request of the FDA, the trial was still blinded at that time. The blinded assessment of the primary outcome was done through both in-person interviews and over the telephone. POWER: 86% to detect a 1-point difference in the group’s first primary outcome.

Stroke 97